Pomalidomide

泊马度胺

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NamePomalidomide
Drug Alias NamePomalidomida珀玛度胺PomalidomidumPomalystImnovid +[12] 
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue
Mechanisms of ActionInterleukin-6 inhibitorsTumor necrosis factor α inhibitorsDNA-binding protein Ikaros degraders +[5] 
TargetsInterleukin-6Tumor necrosis factor αDNA-binding protein Ikaros +[5] 
Therapy Area/IndicationsSolid tumoursGraft vs Host DiseaseScleroderma, Systemic +[32] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2013/02/08
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyThe University Of ChicagoNational Cancer Institute +[7] 
Inactive CompaniesWeill Medical College of Cornell UniversityWashington University School Of MedicineKirby Institute +[12] 
Active IndicationsCentral Nervous System NeoplasmsMultiple MyelomaMedulloblastoma +[9] 
Inactive IndicationsSolid tumoursGraft vs Host DiseaseScleroderma, Systemic +[23] 

Other Information

ATC CodeL04AX06
Related LinksWikipediaDrugBankKEGG